Boston Scientific just finished the first human clinical trial of its new IntellaTip MiFi XP Ablation Catheter for treatment of type 1 atrial flutter. The device is designed to be smaller than its competitors, but provide higher resolution ability to map cardiac tissue when performing ablations.
The hope is that with improved imaging, ablation procedures can be performed with greater precision and the amount of energy delivered to the target tissue can be reduced.
More from Boston Sci:
This single center feasibility trial enrolled 10 patients and was led by Prash Sanders, MBBS, PhD, FHRS, director of the Centre for Heart Rhythm Disorders at the University of Adelaide and the Royal Adelaide Hospital.
Patients with type 1 atrial flutter may exhibit symptoms that include palpitations, shortness of breath, fatigue, lightheadedness and fainting. Catheter ablation, a procedure in which localized electrical energy is delivered into the heart tissue aimed at restoring the continuous normal rhythm, has become a first-line treatment approach for patients with recurrent type 1 atrial flutter and demonstrates more successful short- and long-term outcomes compared to anti-arrhythmic drug therapy.
The IntellaTip MiFi XP Catheter is the first addition to the IntellaTip family of ablation catheters Boston Scientific expects to unveil over the coming years. This new line of ablation catheters is designed to provide physicians with high resolution, precise, multidimensional information through sophisticated micro-sensors at the tip of the catheter.